cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Biocryst Pharmaceuticals Inc
46 own
51 watching
Current Price
$4.43
$-0.07
(-1.56%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,069.59M
52-Week High
52-Week High
9.07000
52-Week Low
52-Week Low
4.27000
Average Volume
Average Volume
4.69M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,069.59M
icon52-Week High9.07000
icon52-Week Low4.27000
iconAverage Volume4.69M
iconDividend Yield--
iconP/E Ratio--
What does the Biocryst Pharmaceuticals Inc do?
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea; Seqirus UK Limited for the development and commercialization of RAPIVAB worldwide, except Japan, Taiwan, Korea, and Israel; and the University of Alabama at Birmingham for the development of influenza neuraminidase and complement inhibitors. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Read More
How much money does Biocryst Pharmaceuticals Inc make?
News & Events about Biocryst Pharmaceuticals Inc.
Stock Options Channel
9 months ago
Investors in BioCryst Pharmaceuticals Inc (BCRX) saw new options begin trading this week, for the July 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the...
PR Newswire
11 months ago
Thinking about buying stock in ImmunoGen, Mersana Therapeutics, Unisys, Eyepoint Pharmaceuticals, or BioCryst Pharmaceuticals? Thinking about buying stock in ImmunoGen, Mersana Therapeutics, Unisys, Eyepoint Pharmaceuticals, or BioCryst Pharmaceuticals? PR Newswire NEW YORK, May 3, 2023 NEW YORK...
Globe Newswire
1 year ago
RESEARCH TRIANGLE PARK, N.C., April 12, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the following investor conferences: The 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19th at 8:45 a.m. ET The BofA ...
Globe Newswire
1 year ago
RESEARCH TRIANGLE PARK, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Dr. Nancy Hutson as chair of its board of directors, effective immediately. I am honored to succeed Bob Ingram. He was a model of effective board ...
Frequently Asked Questions
Frequently Asked Questions
What is Biocryst Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Biocryst Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Biocryst Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Biocryst Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Biocryst Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Biocryst Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Biocryst Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Biocryst Pharmaceuticals Inc?
plus_minus_icon
What percentage is Biocryst Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Biocryst Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$4.43
$-0.07
(-1.56%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00